Abstracts Archive - Page 757 of 2607 - ACR Meeting Abstracts

Abstract Number: 0778 • ACR Convergence 2021
Autologous Stem Cell Transplantation with CD34-Selected Peripheral Blood Stem Cells in Patients with Treatment-Resistant Juvenile-Onset Systemic Sclerosis
Kathryn Torok¹, Franziska Rosser², Kirsten Rose-Felker¹, Vibha Sood¹, Geoffrey Kurland¹, Adam Olson¹, Meghan Frost¹, Vickie Vandergrift¹, Shawna McIntyre¹, Alisha Maslanka³, Kaila Schollaert-Fitch¹, Jessie Barnum¹ and Paul Szabolcs¹, ¹University of Pittsburgh, Pittsburgh, PA, ²UPMC Children's Hospital of Pittbsurgh, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh
Background/Purpose: Juvenile-onset systemic sclerosis (jSSc) is a rare autoimmune disease associated with life-threatening multi-organ inflammation and fibrosis. As in adults, jSSc organ involvement includes vascular,…
Abstract Number: 0779 • ACR Convergence 2021
Predictors of Mortality in a Series of 1528 Brazilian Childhood-onset Systemic Lupus Erythematosus Patients
Ana Paula Sakamoto¹, Clovis Artur Silva², Aline Islabão³, Glaucia Novak⁴, Beatriz Molinari⁴, Rosa Pereira², Claudia Saad-Magalhães⁵, Gleice Clemente⁶, Melissa Fraga⁶, Daniela Petry Pioto⁷, Claudio Len⁸, Rogerio do Prado⁷ and Maria Terreri⁸, ¹Federal University of So Paulo (UNIFESP), São Paulo, Brazil, ²Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Pediatric Rheumatology Unit, Hospital da Criança de Brasília Jose Alencar, Brasilia, DF, Brazil, ⁴Pediatric Rheumatology Unit, Children’s Institute, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵Pediatric Rheumatology Division, São Paulo State University (UNESP) – Faculdade de Medicina de Botucatu, Botucatu, Botucatu, Brazil, ⁶Universidade Federal de São Paulo, São Paulo, Brazil, ⁷Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, SP, Brazil, ⁸Unifesp, São Paulo, Brazil
Background/Purpose: Childhood-onset Systemic lupus erythematosus (cSLE) is an inflammatory autoimmune disease known for its complex and variable clinical presentation and disease course. Its severity may…
Abstract Number: 0780 • ACR Convergence 2021
High Adolescent Health Needs and Relationship to Disease in Patients with Childhood-Onset Systemic Lupus Erythematosus
Chelsea DeCoste¹, Paris Moaf¹, Lawrence Ng¹, Dragana Ostojic-Aitkens¹, Fatima Faruq², Byran Maguire³, Deborah Levy¹, Linda Hiraki¹, Alene Toulany¹ and Andrea Knight⁴, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Research Institute, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE), with typical onset in adolescence, is a chronic life-threatening disease. In addition to dealing with cSLE, these adolescents endure…
Abstract Number: 0781 • ACR Convergence 2021
Long-Term Follow-up of Juvenile Localized Scleroderma Patients Treated with Methotrexate-Based Standardized Regimens (Consensus Treatment Plans)
Suzanne Li¹, Aaron Thammavongxay², Maria Ibarra³, Kathryn Torok⁴, Polly Ferguson⁵, C Egla Rabinovich⁶, Robert Fuhlbrigge⁷, Katie Stewart⁸, Elena Pope⁹, Ronald Laxer¹⁰, Sandy Hong¹¹, Thomas Mason¹², Mara Becker¹³, Gloria Higgins¹⁴, Fatma Dedeoglu¹⁵ and for the CARRA Legacy Registry¹⁶, ¹Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, West Orange, NJ, ²Bergen Academies, Hackensack, NJ, ³Children's Mercy Hospital, Kansas City, MO, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Iowa Carver College of Medicine, Iowa City, IA, ⁶Duke Childrens Hospital & Health Center, Durham, NC, ⁷University of Colorado, Denver, CO, ⁸UT Southwestern, Dallas, TX, ⁹Hospital for Sick Kids, Toronto, ON, Canada, ¹⁰SickKids, Toronto, ON, Canada, ¹¹University of Iowa Stead Family Children's Hospital, Iowa City, IA, ¹²Mayo Clinic, Rochester, MN, ¹³Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC, ¹⁴Ohio State University, Columbus, OH, ¹⁵Boston Children's Hospital, Boston, MA, ¹⁶Childhood Arthritis and Rheumatology Research Alliance, Milwaukee, WI
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare chronic inflammatory and fibrosing disease associated with a high risk for morbidity in children. Methotrexate (MTX) has…
Abstract Number: 0782 • ACR Convergence 2021
Examining the Association of Socioenvironmental Factors with Depression and Anxiety Symptoms Among Youth with Childhood-Onset Systemic Lupus Erythematosus
Dragana Ostojic-Aitkens¹, Ashley Danguecan¹, Sarah Mossad¹, Michelle Quilter¹, Daphne Korczak², Reva Schachter³, Katherine Cost¹, Julie Couture⁴, Daniela Dominguez⁵, Lawrence Ng⁵, Paris Moaf⁶, Tala El Tal⁷, Deborah Levy⁵, Linda Hiraki⁵ and Andrea Knight¹, ¹Hospital for Sick Children, Toronto, ON, Canada, ²Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³Sickkids Toronto, Toronto, ON, Canada, ⁴CHU de Qubec, Québec City, QC, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶Hospital for Sick Children, Toronto, ON, ⁷University of Toronto/Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Depression and anxiety symptoms are prevalent in youth with childhood-onset system lupus erythematosus (cSLE). Healthcare disparities and trauma are associated with adverse mental health…
Abstract Number: 0783 • ACR Convergence 2021
Transmission Disequilibrium Testing Meets Next Generation Sequencing: Applying TDT to Whole Genome Data in Childhood-Onset Systemic Lupus Erythematosus
Kathleen Vazzana¹, Anthony Musolf², Joan Bailey-Wilson³, Zuoming Deng³, Mariana Kaplan³ and Laura Lewandowski², ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)/Children's National Hospital, Washington, DC, ²NIAMS, NIH, Rockville, MD, ³National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder that is more severe in children than adults. Due to aggressive disease in childhood-onset SLE…
Abstract Number: 0784 • ACR Convergence 2021
Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-Onset Systemic Lupus Erythematosus in North America
Laura Cannon¹, Scott Wenderfer², Laura Lewandowski³, Jennifer Cooper⁴, Beatrice Goilav⁵, Andrea Knight⁶, Aimee Hersh⁷, Stacy Ardoin⁸ and Rebecca Sadun¹, ¹Duke University, Durham, NC, ²Baylor College of Medicine, Houston, TX, ³NIAMS, NIH, Rockville, MD, ⁴University of Colorado/Children's Hospital Colorado, Denver, CO, ⁵Children's Hospital at Montefiore, Bronx, NY, ⁶Hospital for Sick Children, Toronto, ON, Canada, ⁷University of Utah, Salt Lake City, UT, ⁸Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) has higher rates of lupus nephritis (LN) than adult-onset SLE, often requiring intensive immunosuppression. This study examined North American…
Abstract Number: 0785 • ACR Convergence 2021
Decreased Peripheral Blood Natural Killer Cell Count in Untreated Juvenile Dermatomyositis Is Associated with Muscle Weakness
Amer Khojah¹, Ameera Bukhari², Chi Trinh³, Gabrielle Morgan⁴ and Lauren Pachman⁵, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Department of Microbiology and Immunology, Loyola University Chicago, Chicago, IL, ³Stanley Manne Research Center, Chicago, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare pediatric autoimmune disease characterized by muscle and skin inflammation. The Pathophysiology of JDM is complex; it involves both…
Abstract Number: 0786 • ACR Convergence 2021
Diagnostic Utility of FibroScan in Screening for Liver Injury in Patients with Inflammatory Arthritis on Treatment with Methotrexate (MTX)
Saman Darabian¹, john Wade², Stefanie Wade³, Jason Kur² and Maziar Badii², ¹University of British Columbia, North Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Methotrexate (MTX) is often the primary medication to treat various rheumatic diseases, including rheumatoid arthritis, psoriasic arthritis and many other inflammatory diseases. MTX is…
Abstract Number: 0787 • ACR Convergence 2021
Association of Hemoglobin Levels and Radiographic Progression in the BRASS Registry
Nancy Shadick¹, Owen Hagino², Amy Praestgaard³, Stefano Fiore², Michael Weinblatt⁴ and Gerd Burmester⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Sanofi, Bridgewater, NJ, ³Sanofi, Cambridge, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: To evaluate baseline hemoglobin (Hb) and radiographic progression over time for patients in the Brigham and Women’s Hospital Rheumatoid Arthritis Sequential Study (BRASS) registry.Methods:…
Abstract Number: 0788 • ACR Convergence 2021
Red Cell Distribution Width Is Associated with Baseline 25-hydroxyvitamin D Level Before Methotrexate Therapy in Rheumatoid Arthritis
Shahdi Malakooti¹, Brigid Wilson², Taissa Bej², Lenche Kostadinova³, Alyssa Lange², Megan O'Mara², David Zidar², Maya Mattar⁴ and Donald Anthony⁵, ¹Case Western Reserve University, UH Cleveland Medical Center, VA Medical Center, Cleveland, OH, ²VA Medical Center, Cleveland, OH, ³UH Cleveland Medical Center, VA Medical Center, Cleveland, OH, ⁴Louis Stokes VA Medical Center, Mayfield Heights, OH, ⁵Case, VA, Metro, Chardon, OH
Background/Purpose: Peripheral blood red cell distribution width (RDW) correlates with disease activity in rheumatoid arthritis (RA) and is associated with subsequent mortality in non-RA patient…
Abstract Number: 0789 • ACR Convergence 2021
Adipokine Levels and Associations with Achievement of Low Disease Activity in Rheumatoid Arthritis
Joshua Baker¹, Bryant England², Michael George¹, Katherine Wysham³, Gail Kerr⁴, Andreas Reimold⁵, Paul Monach⁶, Gary Kunkel⁷, Brian Sauer⁷, Bartlett Hamilton⁸, Carlos Hunter², Michael Duryee², Geoffrey Thiele² and Ted Mikuls², ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁵University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ⁶Brigham and Women's Hospital, Boston, MA, ⁷University of Utah, Salt Lake City, UT, ⁸University of Nebraska, Omaha, NE
Background/Purpose: Adipokines are fat-secreted proteins that serve as metabolic regulators. Prior studies have identified associations between adipokines and disease characteristics such as disease activity and…
Abstract Number: 0790 • ACR Convergence 2021
Unraveling Heterogeneity Within ACPA-negative Rheumatoid Arthritis; The Subgroup of Patients with a Strong Clinical and Serological Response to Initiation of DMARD-treatment Favor Disease Resolution
Marloes Verstappen¹, Hanna van Steenbergen², Pascal de Jong³ and Annette H.M van der Helm-van Mil¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden Univeristy Medical Center, Leiden, Netherlands, ³Erasmus MC, Hendrik Ido Ambacht, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a heterogeneous disease, especially ACPA-negative-RA. This is reflected by differences in long-term outcomes, ranging from refractory RA to sustained-DMARD-free-remission(SDFR; sustained…
Abstract Number: 0791 • ACR Convergence 2021
Most Rheumatoid Arthritis (RA) Patients from Routine Care Reported in 2008-2021 Have Improved Outcomes vs Earlier Eras, but Most Remain in Moderate/high Disease Activity Rather Than Low Activity/remission: Are New Strategies for Earlier Treatment Needed in Addition to New Agents?
Juan Schmukler¹, Kyle Schroeder² and Theodore Pincus², ¹Mount Sinai Hospital - Rheumatology, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: Treatment of rheumatoid arthritis (RA) has been advanced considerably by biological agents with capacity for stringent control of inflammation. A “treat-to-target” directive toward remission…
Abstract Number: 0792 • ACR Convergence 2021
Remission Rates of Patients with Rheumatoid Arthritis in a Tertiary Care
Nils Gildemeister¹, Imke Redeker², Bjoern Buehring¹, Ioana Andreica¹, David Kiefer³, Xenofon Baraliakos¹, Juergen Braun¹ and Uta Kiltz¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²German Rheumatism Research Centre (DRFZ), Berlin, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Essen, Germany
Background/Purpose: The main goal of treatment for patients (pts.) with rheumatoid arthritis (RA) is to achieve remission, in order to both, preserve physical function and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].